Document:

EX-4.2

 Exhibit 4.2 

EXECUTION VERSION 

CIRIUS THERAPEUTICS, INC. 

AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT (the “Agreement”) is entered into as of August 23, 2018, by and among CIRIUS THERAPEUTICS, INC., a Delaware corporation (the
“Company”) and the investors listed on EXHIBIT A hereto, referred to hereinafter as the “Investors” and each individually as an
“Investor.” 
 RECITALS 

WHEREAS, certain of the Investors are purchasing shares of the Company’s
Series A-2 Preferred Stock (the “Series A-2 Stock”) and/or Series A-3 Preferred Stock (the
“Series A-3 Stock”) pursuant to that certain Amended and Restated Series A-2/A-3 Preferred Stock
Purchase Agreement (as the same may be amended or restated from time-to-time, the “Purchase Agreement”) of even date herewith (the
“Financing”); 
 WHEREAS, the obligations in the Purchase
Agreement are conditioned upon the execution and delivery of this Agreement; 
 WHEREAS, certain of the Investors (the
“Existing Investors”) are holders of the Company’s Series A-1 Preferred Stock (the “Series A-1 Stock”) and/or
Series A-2 Stock (the Series A-1 Stock together with the Series A-2 Stock and Series
A-3 Stock, the “Series Preferred”); 
 WHEREAS, the
Existing Investors and the Company are parties to that certain Investor Rights Agreement, dated as of March 24, 2017 (the “Prior Agreement”); 

WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior Agreement
and accept the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement; and 

WHEREAS, in connection with the consummation of the Financing, the parties desire to enter
into this Agreement in order to grant registration, information rights and other rights to the Investors as set forth below. 

NOW, THEREFORE, in consideration of these premises and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 SECTION 1. GENERAL. 

1.1    Definitions. As used in this Agreement the following terms shall have the following respective
meanings: 

  
 1. 

 (a)    “Charter” means the Company’s
Amended and Restated Certificate of Incorporation, as the same may be amended or restated from time to time. 

(b)    “Common Stock” means shares of the Company’s common stock, par value $0.001 per
share. 
 (c)    “Exchange Act” means the Securities Exchange Act of 1934,
as amended. 
 (d)    “Form S-3”
means such form under the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 

(e)    “Holder” means any person owning of record Registrable Securities that
have not been sold to the public or any assignee of record of such Registrable Securities in accordance with Section 2.9 hereof. 

(f)    “Initial Offering” means the Company’s first firm commitment
underwritten public offering of its Common Stock registered under the Securities Act. 

(g)    “Preferred Directors” shall mean the Series
A-1 Directors and the Series A-2/A-3 Directors. 

(h)    “Preferred Stock” means shares of the Company’s preferred stock, par value
$0.001 per share. 
 (i)    “Register,”
“registered,” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering
of effectiveness of such registration statement or document. 
 (j)    “Registrable
Securities” means (a) Common Stock of the Company issuable or issued upon conversion of the Shares and (b) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant,
right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such above-described securities. Notwithstanding the foregoing, Registrable Securities shall not include any
securities (i) sold by a person to the public either pursuant to a registration statement or Rule 144, or (ii) sold in a private transaction in which the transferor’s rights under Section 2 of this Agreement are not assigned.

 (k)    “Registrable Securities then outstanding” shall be the number of
shares of the Company’s Common Stock that are Registrable Securities and either (a) are then issued and outstanding or (b) are issuable pursuant to then exercisable or convertible securities. 

(l)    “Registration Expenses” shall mean all expenses incurred by the Company
in complying with Sections 2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and disbursements not to exceed $35,000
of a single special counsel for the Holders, blue sky fees and expenses and the expense of any special audits incident to or 

  
 2. 

 
required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company). 

(m)    “SEC” or “Commission” means the Securities and
Exchange Commission. 
 (n)    “Securities Act” shall mean the Securities
Act of 1933, as amended. 
 (o)    “Selling Expenses” shall mean all
underwriting discounts and selling commissions applicable to the sale. 
 (p)    “Series A-1 Director” shall mean a director of the Company that the holders of record of the Series A-1 Stock are entitled to elect and have elected pursuant to the
Charter. 
 (q)    “Series
A-2/A-3 Director” shall mean a director of the Company that the holders of record of the Series A-2 Stock and Series
A-3 Stock are entitled to elect and have elected pursuant to the Charter. 

(r)    “Shares” shall mean shares of Series Preferred held from time to time
by the Investors and their permitted assigns. 
 (s)    “Special Registration Statement”
shall mean (i) a registration statement relating to any employee benefit plan or (ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act, any registration statements related to the
issuance or resale of securities issued in such a transaction or (iii) a registration related to stock issued upon conversion of debt securities. 

SECTION 2. REGISTRATION; RESTRICTIONS ON TRANSFER. 

2.1    Restrictions on Transfer. 

(a)    Each Holder agrees not to make any disposition of all or any portion of the Shares or Registrable Securities
unless and until: 
 (i)    there is then in effect a registration statement under the Securities Act covering
such proposed disposition and such disposition is made in accordance with such registration statement; or 

(ii)    (A) The transferee has agreed in writing to be bound by the terms of this Agreement, (B) such
Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (C) if reasonably requested by the Company, such
Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act. It is agreed that the Company will not require
opinions of counsel for transactions made pursuant to Rule 144, except in unusual circumstances. After its Initial Offering, the Company will not require any transferee pursuant to Rule 144 to be bound by the

  
 3. 

 
terms of this Agreement if the shares so transferred do not remain Registrable Securities hereunder following such transfer. 

(b)    Notwithstanding the provisions of subsection (a) above, no such restriction shall apply to a transfer by
a Holder that is (A) a partnership transferring to its partners or former partners in accordance with partnership interests, (B) a corporation transferring to a wholly-owned subsidiary or a parent corporation that owns all of the capital
stock of the Holder, (C) a limited liability company transferring to its members or former members in accordance with their interest in the limited liability company, or (D) an individual transferring to the Holder’s family member or
trust for the benefit of an individual Holder; provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if he were an original Holder hereunder. 

(c)    Each certificate representing Shares or Registrable Securities shall be stamped or otherwise imprinted with
legends substantially similar to the following (in addition to any legend required under applicable state securities laws): 
 THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR
UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 

THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A
CERTAIN AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 

(d)    The Company shall be obligated to reissue promptly unlegended certificates at the request of any Holder
thereof if the Company has completed its Initial Offering and the Holder shall have obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be
disposed of may lawfully be so disposed of without registration, qualification and legend, provided that the second legend listed above shall be removed only at such time as the Holder of such certificate is no longer subject to any
restrictions hereunder. 
 (e)    Any legend endorsed on an instrument pursuant to applicable state securities
laws and the stop-transfer instructions with respect to such securities shall be removed 

  
 4. 

 
upon receipt by the Company of an order of the appropriate blue sky authority authorizing such removal. 

2.2    Demand Registration. 

(a)    Subject to the conditions of this Section 2.2, if the Company shall receive a written request from the
Holders of a majority of the Registrable Securities (the “Initiating Holders”) that the Company file a registration statement under the Securities Act covering the registration of at least a majority of the Registrable
Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed $10,000,000), then the Company shall, within thirty (30) days of the receipt thereof, give
written notice of such request to all Holders, and subject to the limitations of this Section 2.2, effect, as expeditiously as reasonably possible, the registration under the Securities Act of all Registrable Securities that all Holders request
to be registered. 
 (b)    If the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.2 or any request pursuant to Section 2.4 and the Company shall include such information in the written
notice referred to in Section 2.2(a) or Section 2.4(a), as applicable. In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such
underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement
in customary form with the underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable Securities held by all Initiating Holders (which underwriter or underwriters shall be reasonably acceptable to the
Company). Notwithstanding any other provision of this Section 2.2 or Section 2.4, if the underwriter advises the Company that marketing factors require a limitation of the number of securities to be underwritten (including Registrable
Securities) then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such
Registrable Securities on a pro rata basis based on the number of Registrable Securities held by all such Holders (including the Initiating Holders). Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn
from the registration. 
 (c)    The Company shall not be required to effect a registration pursuant to this
Section 2.2: 
 (i)    prior to the earlier of (A) the third anniversary of the date of this Agreement
or (B) of the expiration of the restrictions on transfer set forth in Section 2.11 following the Initial Offering; 

(ii)    after the Company has effected two (2) registrations pursuant to this Section 2.2, and such
registrations have been declared or ordered effective; 

  
 5. 

 (iii)    during the period starting with the date of filing of,
and ending on the date one hundred eighty (180) days following the effective date of the registration statement pertaining to the Initial Offering (or such longer period as may be determined pursuant to Section 2.11 hereof);
provided that the Company makes reasonable good faith efforts to cause such registration statement to become effective; 

(iv)    if within thirty (30) days of receipt of a written request from Initiating Holders pursuant to
Section 2.2(a), the Company gives notice to the Holders of the Company’s intention to file a registration statement for its Initial Offering within ninety (90) days; 

(v)    if the Company shall furnish to Holders requesting a registration statement pursuant to this
Section 2.2 a certificate signed by the Chairman of the Board stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration
statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of the request of the Initiating Holders; provided that such right
to delay a request shall be exercised by the Company not more than once in any twelve (12) month period; 

(vi)    if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 pursuant to a request made pursuant to Section 2.4 below; or 

(vii)    in any particular jurisdiction in which the Company would be required to qualify to do business or to
execute a general consent to service of process in effecting such registration, qualification or compliance. 

2.3    Piggyback Registrations. The Company shall notify all Holders of Registrable Securities in writing at
least fifteen (15) days prior to the filing of any registration statement under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary
offerings of securities of the Company, but excluding Special Registration Statements) and will afford each such Holder an opportunity to include in such registration statement all or part of such Registrable Securities held by such Holder. Each
Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall, within fifteen (15) days after the above-described notice from the Company, so notify the Company in writing. Such
notice shall state the intended method of disposition of the Registrable Securities by such Holder. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall
nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and
conditions set forth herein. 
 (a)    Underwriting. If the registration statement of which the Company
gives notice under this Section 2.3 is for an underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to include 

  
 6. 

 
Registrable Securities in a registration pursuant to this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s
Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or
underwriters selected for such underwriting by the Company. Notwithstanding any other provision of this Agreement, if the Company determines in good faith, based on consultation with the underwriter, that marketing factors require a limitation of
the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated, first, to the Company; second, to the Holders on a pro rata basis based on the total number of Registrable Securities
held by the Holders; and third, to any stockholder of the Company (other than a Holder) on a pro rata basis; provided, however, that no such reduction shall reduce the amount of securities of the selling Holders included in the
registration below thirty percent (30%) of the total amount of securities included in such registration, unless such offering is the Initial Offering and such registration does not include shares of any other selling stockholders, in which event any
or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding clause. In no event will shares of any other selling stockholder be included in such registration that would reduce the number of shares
which may be included by Holders without the written consent of Holders of not less than sixty-six and two-thirds percent (66 2/3%) of the Registrable Securities
proposed to be sold in the offering. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least ten (10) business days
prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder which is a partnership, limited liability
company or corporation, the partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of any such partners, retired partners, members and retired members and any trusts for the benefit of
any of the foregoing person shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all
entities and individuals included in such “Holder,” as defined in this sentence. 
 (b)    Right to
Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.3 whether or not any Holder has elected to include securities in such registration, and shall promptly
notify any Holder that has elected to include shares in such registration of such termination or withdrawal. The Registration Expenses of such withdrawn registration shall be borne by the Company in accordance with Section 2.5 hereof. 

2.4    Form S-3 Registration. In case the Company shall receive from
any Holder or Holders of Registrable Securities a written request or requests that the Company effect a registration on Form S-3 (or any successor to Form S-3)
or any similar short-form registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will: 

(a)    promptly give written notice of the proposed registration, and any related qualification or compliance, to
all other Holders of Registrable Securities; and 

  
 7. 

 (b)    as soon as practicable, effect such registration and all
such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together
with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company;
provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.4: 

(i)    if Form S-3 is not available for such offering by the Holders,
or 
 (ii)    if the Holders, together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than one million dollars ($1,000,000), or 

(iii)    if within thirty (30) days of receipt of a written request from any Holder or Holders pursuant to
this Section 2.4, the Company gives notice to such Holder or Holders of the Company’s intention to make a public offering within ninety (90) days, other than pursuant to a Special Registration Statement; or 

(iv)    if the Company shall furnish to the Holders a certificate signed by the Chairman of the Board of Directors
of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 registration to be
effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than ninety (90) days after receipt of the
request of the Holder or Holders under this Section 2.4; provided, that such right to delay a request shall be exercised by the Company not more than once in any twelve (12) month period, or 

(v)    in any particular jurisdiction in which the Company would be required to qualify to do business or to
execute a general consent to service of process in effecting such registration, qualification or compliance. 

(c)    Subject to the foregoing, the Company shall file a Form S-3
registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the requests of the Holders. Registrations effected pursuant to this Section 2.4 shall not be
counted as demands for registration or registrations effected pursuant to Section 2.2. 
 2.5    Expenses
of Registration. Except as specifically provided herein, all Registration Expenses incurred in connection with any registration, qualification or compliance pursuant to Section 2.2, 2.3 or 2.4 herein shall be borne by the Company. All
Selling Expenses incurred in connection with any registrations hereunder, shall be borne by the holders of the securities so registered pro rata on the basis of the number of shares so registered. The Company shall not, however, be required
to pay for expenses of any registration proceeding begun pursuant to Section 2.2 or 2.4, the request of which has been subsequently withdrawn by 

  
 8. 

 
the Initiating Holders unless (a) the withdrawal is based upon material adverse information concerning the Company of which the Initiating Holders were not aware at the time of such request
or (b) the Holders of a majority of Registrable Securities agree to deem such registration to have been effected as of the date of such withdrawal for purposes of determining whether the Company shall be obligated pursuant to
Section 2.2(c) to undertake any subsequent registration, in which event such right shall be forfeited by all Holders. If the Holders are required to pay the Registration Expenses, such expenses shall be borne by the holders of securities
(including Registrable Securities) requesting such registration in proportion to the number of shares for which registration was requested. If the Company is required to pay the Registration Expenses of a withdrawn offering pursuant to
clause (a) above, then such registration shall not be deemed to have been effected for purposes of determining whether the Company shall be obligated pursuant to Section 2.2(c) or 2.4(b)(5), as applicable, to undertake any subsequent
registration. 
 2.6    Obligations of the Company. Whenever required to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a)    prepare and file
with the SEC a registration statement with respect to such Registrable Securities and use all reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for up to thirty (30) days or, if earlier, until the Holder or Holders have completed the distribution related thereto; provided, however, that at any time, upon
written notice to the participating Holders and for a period not to exceed sixty (60) days thereafter (the “Suspension Period”), the Company may delay the filing or effectiveness of any registration statement or suspend
the use or effectiveness of any registration statement (and the Initiating Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the Suspension Period) if the Company reasonably believes
that there is or may be in existence material nonpublic information or events involving the Company, the failure of which to be disclosed in the prospectus included in the registration statement could result in a Violation (as defined below). In the
event that the Company shall exercise its right to delay or suspend the filing or effectiveness of a registration hereunder, the applicable time period during which the registration statement is to remain effective shall be extended by a period of
time equal to the duration of the Suspension Period. The Company may extend the Suspension Period for an additional consecutive sixty (60) days with the consent of the holders of not less than sixty-six
and two-thirds percent (66 2/3%) of the Registrable Securities registered under the applicable registration statement, which consent shall not be unreasonably withheld. No more than one (1) such
Suspension Periods shall occur in any twelve (12) month period. In no event shall any Suspension Period, when taken together with all prior Suspension Periods, exceed 120 days in the aggregate. If so directed by the Company, all Holders
registering shares under such registration statement shall (i) not offer to sell any Registrable Securities pursuant to the registration statement during the period in which the delay or suspension is in effect after receiving notice of such
delay or suspension; and (ii) use their best efforts to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Holders’ possession, of the prospectus relating to such Registrable
Securities current at the time of receipt of such notice. Notwithstanding the foregoing, the Company shall not be required to file, cause to become effective or maintain the effectiveness of any registration statement other than a registration
statement on Form S-3 that contemplates a 

  
 9. 

 
distribution of securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act. 

(b)    Prepare and file with the SEC such amendments and supplements to such registration statement and the
prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth
in subsection (a) above. 
 (c)    Furnish to the Holders such number of copies of a prospectus, including a
preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d)    Use its reasonable efforts to register and qualify the securities covered by such registration statement
under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or
to file a general consent to service of process in any such states or jurisdictions. 
 (e)    In the event of any
underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter
into and perform its obligations under such an agreement. 
 (f)    Notify each Holder of Registrable Securities
covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company
will use reasonable efforts to amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances then existing. 
 (g)    Use its reasonable
efforts to furnish, on the date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company
for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a letter, dated as of such date, from the independent
certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters. 

2.7    Delay of Registration; Furnishing Information. 

  
 10. 

 (a)    No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

(b)    It shall be a condition precedent to the obligations of the Company to take any action pursuant to
Section 2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall be required to
effect the registration of their Registrable Securities. 
 (c)    The Company shall have no obligation with
respect to any registration requested pursuant to Section 2.2 or Section 2.4 if the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the
number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in Section 2.2 or Section 2.4, whichever is applicable. 

2.8    Indemnification. In the event any Registrable Securities are included in a registration statement
under Sections 2.2, 2.3 or 2.4: 
 (a)    To the extent permitted by law, the Company will indemnify and hold
harmless each Holder, the partners, members, officers and directors of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the
Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”) by the Company: (i) any untrue statement or
alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto,
(ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities
Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such registration statement; and the Company will
reimburse each such Holder, partner, member, officer, director, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or
action; provided however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent
of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in
reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder, partner, member, officer, director, underwriter or controlling person of such Holder. 

  
 11. 

 (b)    To the extent permitted by law, each Holder will, if
Registrable Securities held by such Holder are included in the securities as to which such registration qualifications or compliance is being effected, severally but not jointly, indemnify and hold harmless the Company, each of its directors, its
officers and each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, directors or
officers or any person who controls such Holder, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, director,
officer or controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or
are based upon any of the following statements: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or final
prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or
(iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection
with the offering covered by such registration statement (collectively, a “Holder Violation”), in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance upon and in conformity with
written information furnished by such Holder to the Company expressly for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer,
controlling person, underwriter or other Holder, or partner, officer, director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action if it is judicially determined
that there was such a Holder Violation; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided further, that in no event shall any indemnity under this Section 2.8 exceed the net proceeds from the offering received
by such Holder. 
 (c)    Promptly after receipt by an indemnified party under this Section 2.8 of notice of
the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, deliver to the indemnifying party a written
notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof
with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses thereof to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure
to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8 to the extent, and only
to the extent, prejudicial to its ability to defend such action, but the omission so to 

  
 12. 

 
deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8. 

(d)    If the indemnification provided for in this Section 2.8 is held by a court of competent jurisdiction to
be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law
contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the
indemnified party on the other in connection with the Violation(s) or Holder Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations. The relative fault of the indemnifying party
and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, that in no event shall any contribution
by a Holder hereunder exceed the net proceeds from the offering received by such Holder. 
 (e)    The obligations
of the Company and Holders under this Section 2.8 shall survive completion of any offering of Registrable Securities in a registration statement and, with respect to liability arising from an offering to which this Section 2.8 would apply
that is covered by a registration filed before termination of this Agreement, such termination. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any
judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. 

2.9    Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities
pursuant to this Section 2 may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a subsidiary, parent, general partner, limited partner,
retired partner, member or retired member, or stockholder of a Holder that is a corporation, partnership or limited liability company, (b) is a Holder’s family member or trust for the benefit of an individual Holder, or (c) acquires
at least 1,000,000 shares of Registrable Securities (as adjusted for stock splits and combinations); or (d) is an entity affiliated by common control (or other related entity) with such Holder provided, however, (i) the transferor
shall, within ten (10) days after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned and
(ii) such transferee shall agree to be subject to all restrictions set forth in this Agreement. 

2.10    Limitation on Subsequent Registration Rights. Other than as provided in Section 4.9, after the
date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company that would grant such holder rights to demand the registration of shares of the Company’s capital
stock, or to include such shares in a registration statement that would reduce the number of shares includable by the Holders. 

  
 13. 

 2.11    Market
Stand-Off Agreement. Each Holder hereby agrees that such Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or
similar transaction with the same economic effect as a sale, any shares of Common Stock (or other securities) of the Company held by such Holder (other than those included in the registration) during the
180-day period following the effective date of the Initial Offering (or such longer period, not to exceed 34 days after the expiration of the 180-day period, as
the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation); provided, that all officers and directors of the Company and holders
of at least one percent (1%) of the Company’s voting securities are bound by and have entered into similar agreements. 

2.12    Agreement to Furnish Information. Each Holder agrees to execute and deliver such other agreements as
may be reasonably requested by the Company or the managing underwriters that are consistent with the Holder’s obligations under Section 2.11 or that are necessary to give further effect thereto. In addition, if requested by the Company or
the representative of the underwriters of Common Stock (or other securities) of the Company, each Holder shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in
connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in Section 2.11 and this Section 2.12 shall not apply to
a Special Registration Statement. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such shares of Common Stock (or other securities) until the end of such period. Each Holder agrees that
any transferee of any shares of Registrable Securities shall be bound by Sections 2.11 and 2.12. The underwriters of the Company’s stock are intended third party beneficiaries of Sections 2.11 and 2.12 and shall have the right, power and
authority to enforce the provisions hereof as though they were a party hereto. 
 2.13    Rule 144 Reporting.
With a view to making available to the Holders the benefits of certain rules and regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to:

 (a)    Make and keep public information available, as those terms are understood and defined in SEC
Rule 144 or any similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public; 

(b)    File with the SEC, in a timely manner, all reports and other documents required of the Company under the
Exchange Act; and 
 (c)    So long as a Holder owns any Registrable Securities, furnish to such Holder forthwith
upon request: a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 of the Securities Act, and of the Exchange Act (at any time after it has become subject to such reporting requirements); a copy of
the most recent annual or quarterly report of the Company filed with the Commission; and such other reports and documents as a Holder may reasonably request in connection with availing itself of any rule or regulation of the SEC allowing it to sell
any such securities without registration. 

  
 14. 

 2.14    Termination of Registration Rights. The right of
any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.2, Section 2.3, or Section 2.4 hereof shall terminate upon the earlier of: (i) the date three (3) years
following an initial public offering that results in the conversion of all outstanding shares of the Company’s Preferred Stock pursuant to the Charter (a “Qualified IPO”); or (ii) such time as such Holder holds less
than 1% of the Company’s outstanding Common Stock (treating all shares of Preferred Stock on an as converted basis), the Company has completed its Initial Offering and all Registrable Securities of the Company issuable or issued upon conversion
of the Shares held by and issuable to such Holder (and its affiliates) may be sold pursuant to Rule 144 without restriction on volume limitations. Upon such termination, such shares shall cease to be “Registrable Securities” hereunder for
all purposes. 
 SECTION 3. COVENANTS OF THE COMPANY AND INVESTORS. 

3.1    Basic Financial Information and Reporting. 

(a)    The Company will maintain true books and records of account in which full and correct entries will be made of
all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles consistently applied (except as noted therein), and will set aside on its books all such proper
accruals and reserves as shall be required under generally accepted accounting principles consistently applied. 

(b)    As soon as practicable after the end of each fiscal year of the Company, and in any event within one hundred
twenty (120) days thereafter, the Company will furnish each Investor that holds at least 1,000,000 Registrable Securities (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like after the date hereof) (each, a
“Major Investor”) a balance sheet of the Company, as at the end of such fiscal year, and a statement of income and a statement of cash flows of the Company, for such year, all prepared in accordance with generally accepted
accounting principles consistently applied (except as noted therein) and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail. Such financial statements shall be accompanied by a report
and opinion thereon by independent public accountants selected by the Company’s Board of Directors, including at least two (2) of the Preferred Directors. 

(c)    The Company will furnish each Major Investor, as soon as practicable after the end of the first, second and
third quarterly accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days thereafter, a balance sheet of the Company as of the end of each such quarterly period, and a statement of income and a
statement of cash flows of the Company for such period and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles consistently applied (except as noted therein), with the exception that no notes
need be attached to such statements and year-end audit adjustments may not have been made. 

(d)    The Company will furnish each Major Investor: (i) at least thirty (30) days prior to the beginning
of each fiscal year an annual budget and operating plans for such fiscal year (and as soon as available, any subsequent written revisions thereto); and (ii) as soon as 

  
 15. 

 
practicable after the end of each month, and in any event within twenty (20) days thereafter, a balance sheet of the Company as of the end of each such month, and a statement of income and a
statement of cash flows of the Company for such month and for the current fiscal year to date, including a comparison to plan figures for such period, prepared in accordance with generally accepted accounting principles consistently applied (except
as noted thereon), with the exception that no notes need be attached to such statements and year-end audit adjustments may not have been made. 

3.2    Inspection Rights. Each Major Investor shall have the right to visit and inspect any of the
properties of the Company or any of its subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of its subsidiaries with its officers, and to review such information as is reasonably requested all at such reasonable
times and as often as may be reasonably requested; provided, however, that the Company shall not be obligated under this Section 3.2 with respect to a competitor of the Company or with respect to information which the Board of Directors
determines in good faith is confidential or attorney-client privileged and should not, therefore, be disclosed. 

3.3    Confidentiality of Records. Each Investor agrees to use the same degree of care as such Investor uses
to protect its own confidential information to keep confidential any information furnished to such Investor pursuant to Section 3.1 and 3.2 hereof that the Company identifies as being confidential or proprietary (so long as such information is
not in the public domain), except that such Investor may disclose such proprietary or confidential information (i) to any partner, subsidiary or parent of such Investor as long as such partner, subsidiary or parent is advised of and agrees or
has agreed to be bound by the confidentiality provisions of this Section 3.3 or comparable restrictions; (ii) at such time as it enters the public domain through no fault of such Investor; (iii) that is communicated to it free of any
obligation of confidentiality; (iv) that is developed by Investor or its agents independently of and without reference to any confidential information communicated by the Company; or (v) as required by applicable law. 

3.4    Reservation of Common Stock. The Company will at all times reserve and keep available, solely for
issuance and delivery upon the conversion of the Preferred Stock, all Common Stock issuable from time to time upon such conversion. 

3.5    Director and Officer Insurance. The Company shall maintain in full force and effect at all times
director and officer liability insurance in the amount of at least $5,000,000, unless the Board of Directors, including all Series A-2/A-3 Directors, determines that
maintaining such insurance would not be in the best interest of the Company and its stockholders. 
 3.6    Observer
Rights. 
 (a)    For so long as Frazier Life Sciences VIII, L.P. (“Frazier”),
together with any of its affiliates, holds at least 1,000,000 Registrable Securities, the Company shall allow one representative designated by Frazier to attend all meetings of the Company’s Board of Directors in a nonvoting capacity, and in
connection therewith, the Company shall, concurrent with delivery to the Board of Directors, give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board of

  
 16. 

 
Directors; provided, however, that the Company reserves the right to exclude any such representative from access to any material or meeting or portion thereof if the Company believes upon
advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential information or for other similar reasons. The decision of the Board with respect to the privileged or
confidential nature of such information shall be final and binding. Such representative shall agree that any confidential information provided to or learned in connection with these observer rights shall be subject to the confidentiality provisions
set forth in this Agreement. 
 (b)    For so long as Novo Holdings A/S (“Novo”), together
with any of its affiliates, holds at least 1,000,000 Registrable Securities, the Company shall allow one representative designated by Novo to attend all meetings of the Company’s Board of Directors in a nonvoting capacity, and in connection
therewith, the Company shall, concurrent with delivery to the Board of Directors, give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board of Directors;
provided, however, that the Company reserves the right to exclude any such representative from access to any material or meeting or portion thereof if the Company believes upon advice of counsel that such exclusion is reasonably necessary to
preserve the attorney-client privilege, to protect highly confidential information or for other similar reasons. The decision of the Board with respect to the privileged or confidential nature of such information shall be final and binding. Such
representative shall agree that any confidential information provided to or learned in connection with these observer rights shall be subject to the confidentiality provisions set forth in this Agreement. 

(c)    For so long as Adams Street 2017 Direct Venture/Growth Fund LP (“ASP”), together with
any of its affiliates, holds at least 1,000,000 Registrable Securities, the Company shall allow one representative designated by ASP to attend all meetings of the Company’s Board of Directors in a nonvoting capacity, and in connection
therewith, the Company shall, concurrent with delivery to the Board of Directors, give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board of Directors;
provided, however, that the Company reserves the right to exclude any such representative from access to any material or meeting or portion thereof if the Company believes upon advice of counsel that such exclusion is reasonably necessary to
preserve the attorney-client privilege, to protect highly confidential information or for other similar reasons. The decision of the Board with respect to the privileged or confidential nature of such information shall be final and binding. Such
representative shall agree that any confidential information provided to or learned in connection with these observer rights shall be subject to the confidentiality provisions set forth in this Agreement. 

(d)    For so long as Metabolic Solutions Development Company, LLC (“MSDC”) holds at least
1,000,000 shares of the Company’s common stock, the Company shall allow one representative designated by MSDC to attend all meetings of the Company’s Board of Directors in a nonvoting capacity, and in connection therewith, the Company
shall, concurrent with delivery to the Board of Directors, give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board of Directors; provided, however,
that the Company reserves the right to exclude any such representative from access to any material or meeting or portion thereof if the Company believes 

  
 17. 

 
upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential information or for other similar reasons. The decision
of the Board with respect to the privileged or confidential nature of such information shall be final and binding. Such representative shall agree that any confidential information provided to or learned in connection with these observer rights
shall be subject to the confidentiality provisions set forth in this Agreement. 
 (e)    For so long as at least
1,000,000 shares of the Company’s Series A-1 Stock remains outstanding, the Company shall allow one representative designated by the holders of a majority of the then-outstanding shares of Series A-1 Stock to attend all meetings of the Company’s Board of Directors in a nonvoting capacity, and in connection therewith, the Company shall, concurrent with delivery to the Board of Directors, give such
representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board of Directors; provided, however, that the Company reserves the right to exclude any such
representative from access to any material or meeting or portion thereof if the Company believes upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential information
or for other similar reasons. The decision of the Board with respect to the privileged or confidential nature of such information shall be final and binding. Such representative shall agree that any confidential information provided to or learned in
connection with these observer rights shall be subject to the confidentiality provisions set forth in this Agreement. 

3.7    Proprietary Information and Inventions Agreement. The Company shall require all employees and
consultants to execute and deliver a Proprietary Information and Inventions Agreement substantially in a form approved by the Company’s counsel or Board of Directors. 

3.8    Intentionally Omitted. 

3.9    Board Approval. The vote or written consent of a majority of the Board of Directors shall be
necessary for the Company to effect or validate any of the following actions (whether by merger, recapitalization or otherwise): 

(a)    Any amendment, alteration, or repeal of any provision of the Charter or the Bylaws of the Company (including
any filing of a Certificate of Designation); 
 (b)    Any increase or decrease in the authorized number of shares
of Common Stock or Preferred Stock; 
 (c)    Any authorization or any designation, whether by reclassification or
otherwise, of any new class or series of stock or any other securities convertible into a new class or series of stock of the Company ranking on a parity with or senior to the Series Preferred in right of redemption, liquidation preference, voting
or dividend rights or any increase in the authorized or designated number of any such class or series; 

(d)    Any redemption, repurchase, payment or declaration of dividends or other distributions with respect to Common
Stock or Preferred Stock (except for acquisitions of 

  
 18. 

 
Common Stock by the Company permitted by Sections 1(c)(i), (ii) and (iii) of Article IV.D of the Charter); 

(e)    Any agreement by the Company or its stockholders regarding an Asset Transfer or Acquisition (each as defined
in the Charter); 
 (f)    Any voluntary dissolution or liquidation of the Company; or 

(g)    Any increase or decrease in the authorized number of members of the Company’s Board of Directors. 

Further, for so long as any shares of Series Preferred remain outstanding, in addition to any other vote or consent required herein, by the
Charter or by law, the vote or written consent of a majority of the Board of Directors, including at least one (1) Series A-1 Director and at least one (1) Series A-2/A-3 Director, shall be necessary for the Company to effect or validate any Liquidation Event (as defined in the Charter) (whether by merger, recapitalization or otherwise) that would be treated as an
asset sale for tax purposes. 
 3.10    Director Expenses and Fees. The Company shall reimburse the non-employee directors for all reasonable out-of-pocket expenses incurred by such directors for travel to and attendance at meetings of
the Company’s Board of Directors or any committee thereof and for expenses reasonably required for performing their duties as directors. The Company will also be responsible for the expenses associated with any observer selected pursuant to
Section 3.6 attending meetings of the Company’s Board of Directors or any committee thereof.    All non-employee directors shall be equally compensated for such member’s
service as a member of the Company’s Board of Directors, unless such compensation is waived by such member with respect to himself or herself. 

3.11    Investor Covenant not to Voluntarily Convert Shares. Notwithstanding the provisions of
Section 4(a) of Article IV.D of the Charter, each Investor that holds Second Tranche Extension Shares (as defined in the Purchase Agreement) hereby covenants and agrees that, at all times during which the Company may hold the Series A-3 Closing (as defined in the Purchase Agreement) pursuant to the terms of the Purchase Agreement, such Investor shall not, without the prior written consent of the holders of at least 66 2/3% of the
then-outstanding Second Tranche Extension Shares, exercise its option to convert the Second Tranche Extension Shares held by such Investor into shares of Common Stock pursuant to the terms of the Charter. At all times during which the Company may
hold the Series A-3 Closing pursuant to the terms of the Purchase Agreement, the Company shall refuse to accept or otherwise recognize an option exercised by the Investor’s holding Second Tranche
Extension Shares that is in violation of the provisions of this Section 3.11. 
 3.12    Termination of
Covenants. All covenants of contained in Section 3 of this Agreement (other than the provisions of Section 3.3 and 3.7) shall expire and terminate as to each Investor upon the earlier of (i) the effective date of the registration
statement pertaining to a Qualified IPO or (ii) upon an Acquisition (as defined in the Charter). 
 SECTION 4. RIGHTS OF FIRST REFUSAL.

  
 19. 

 4.1    Subsequent Offerings. Subject to applicable
securities laws, each Major Investor shall have a right of first refusal to purchase its pro rata share of all Equity Securities, as defined below, that the Company may, from time to time, propose to sell and issue after the date of this
Agreement, other than the Equity Securities excluded by Section 4.6 hereof. Each Investor’s pro rata share is equal to the ratio of (a) the number of shares of the Company’s Common Stock (including all shares of Common
Stock issued or issuable upon conversion of the Shares) of which such Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the total number of shares of the Company’s outstanding Common Stock
(including all shares of Common Stock issued or issuable upon conversion of the Shares) immediately prior to the issuance of the Equity Securities. The term “Equity Securities” shall mean (i) any Common Stock, Preferred
Stock or other security of the Company, (ii) any security convertible into or exercisable or exchangeable for, with or without consideration, any Common Stock, Preferred Stock or other security (including any option to purchase such a
convertible security), (iii) any security carrying any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or other security or (iv) any such warrant or right. 

4.2    Exercise of Rights. If the Company proposes to issue any Equity Securities, it shall give each Major
Investor written notice of its intention, describing the Equity Securities, the price and the terms and conditions upon which the Company proposes to issue the same. Each Major Investor shall have fifteen (15) days from the giving of such
notice to agree to purchase its pro rata share of the Equity Securities for the price and upon the terms and conditions specified in the notice by giving written notice to the Company and stating therein the quantity of Equity Securities to
be purchased. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any Major Investor who would cause the Company to be in violation of applicable federal securities laws by virtue of such offer
or sale. 
 4.3    Issuance of Equity Securities to Other Persons. If not all of the Major Investors elect
to purchase their pro rata share of the Equity Securities, then the Company shall promptly notify in writing the Major Investors who do so elect and shall offer such Major Investors the right to acquire such unsubscribed shares on a pro
rata basis. The Major Investors shall have five (5) days after receipt of such notice to notify the Company of its election to purchase all or a portion thereof of the unsubscribed shares. The Company shall have ninety (90) days
thereafter to sell the Equity Securities in respect of which the Major Investor’s rights were not exercised, at a price not lower and upon general terms and conditions not materially more favorable to the purchasers thereof than specified in
the Company’s notice to the Major Investors pursuant to Section 4.2 hereof. If the Company has not sold such Equity Securities within ninety (90) days of the notice provided pursuant to Section 4.2, the Company shall not
thereafter issue or sell any Equity Securities, without first offering such securities to the Major Investors in the manner provided above. 

4.4    Termination and Waiver of Rights of First Refusal. The rights of first refusal established by this
Section 4 shall not apply to, and shall terminate upon the earlier of (i) the effective date of the registration statement pertaining to the Qualified IPO or (ii) an Acquisition. Notwithstanding Section 5.5 hereof, the rights of
first refusal established by this Section 4 may be amended, or any provision waived with and only with the written consent of the Company and the Major Investors holding a majority of the Registrable Securities held by all Major Investors,
or as permitted by Section 5.5. 

  
 20. 

 4.5    Assignment of Rights of First Refusal. The rights
of first refusal of each Major Investor under this Section 4 may be assigned to the same parties, subject to the same restrictions as any transfer of registration rights pursuant to Section 2.9. 

4.6    Excluded Securities. The rights of first refusal established by this Section 4 shall have no
application to any of the following Equity Securities: 
 (a)    up to 10,204,835 shares of Common Stock and/or
options, warrants or other Common Stock purchase rights and the Common Stock issued pursuant to such options, warrants or other rights (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like after the date hereof),
or such larger amount as approved by the Board of Directors, including at least two (2) Preferred Directors, issued or to be issued after the date hereof to employees, officers or directors of, or consultants or advisors to the Company or any
subsidiary, pursuant to stock purchase or stock option plans or other arrangements that are approved by the Board of Directors provided, however, that any shares of Common Stock (i) not issued pursuant to rights, agreements, option or
warrants (“Unexercised Options”) as a result of the termination of such Unexercised Options or (ii) reacquired by the Company from employees, directors or consultants at no more than cost pursuant to agreements that
permit the Company to repurchase such shares upon termination of services to the Company shall not be counted toward such maximum number unless and until such shares are regranted as shares of Common Stock and/or options, warrants or other Common
Stock purchase rights; 
 (b)    stock issued or issuable pursuant to any rights or agreements, options, warrants
or convertible securities outstanding as of the date of this Agreement; and stock issued pursuant to any such rights or agreements granted after the date of this Agreement, so long as the rights of first refusal established by this Section 4
were complied with, waived, or were inapplicable pursuant to any provision of this Section 4.6 with respect to the initial sale or grant by the Company of such rights or agreements; 

(c)    any Equity Securities issued for consideration other than cash pursuant to a merger, consolidation,
acquisition or similar business combination, approved by the Board of Directors, including at least two (2) Preferred Directors; 

(d)    any Equity Securities issued in connection with any stock split, stock dividend or recapitalization by the
Company; 
 (e)    any Equity Securities issued pursuant to any equipment loan or leasing arrangement, real
property leasing arrangement, or debt financing from a bank or similar financial or lending institution approved by the Board of Directors, including at least two (2) Preferred Directors; 

(f)    any Equity Securities that are issued by the Company pursuant to a registration statement filed under the
Securities Act; 
 (g)    any Equity Securities issued in connection with strategic transactions involving the
Company and other entities, including, without limitation, joint ventures, manufacturing, marketing, distribution, technology transfer or development arrangements; 

  
 21. 

 
provided that the issuance of shares therein has been approved by the Board of Directors, including at least two (2) Preferred Directors; and 

(h)    any Equity Securities issued by the Company pursuant to the terms of Section 2.1, Section 2.2,
Section 2.3 or Section 2.4 of the Purchase Agreement. 
 4.7    No Participation Right for Bad
Actors. No Investor shall be eligible for to participate in the rights provided for in this Section 4 if the Investor or any of its directors, executive officers, other officers that may serve as a director or officer of any company
in which it invests, general partners or managing members or any person that is, or would by exercise of such rights become, a beneficial owner of twenty percent (20%) of more of the securities of the Company (in accordance with Rule 506(d) of
the Securities Act) is subject to any Disqualification Event (as defined in that certain Voting Agreement, dated the date hereof, by and among the Company and the other parties thereto), except for Disqualification Events covered by
Rule 506(d)(2) or (d)(3) under the Securities Act and disclosed in writing in reasonable detail to the Company. 
 SECTION 5. MISCELLANEOUS.

 5.1    Governing Law; Venue. This Agreement shall be governed by and construed under the laws of the
State of Delaware in all respects as such laws are applied to agreements among Delaware residents entered into and to be performed entirely within Delaware, without reference to conflicts of laws or principles thereof. Each of the parties hereto
irrevocably submits to the exclusive jurisdiction of the Chancery Court of the State of Delaware, and any state appellate court therefrom within the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept
jurisdiction over a particular matter, any state or federal court within the State of Delaware) for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated
hereby. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying
of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 

5.2    Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall
inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person who shall be a holder of Registrable
Securities from time to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and address of the transferee, the Company may deem
and treat the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price. 

5.3    Entire Agreement. This Agreement and the Exhibits hereto, the Purchase Agreement and the other
documents delivered pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party 

  
 22. 

 
shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set forth herein and therein. Each party
expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement. Without limiting the generality of the foregoing, and except as otherwise set forth
herein, the Prior Agreement is hereby amended and restated to read as set forth in this Agreement and the Prior Agreement is hereby terminated, waived, released, replaced and superseded in its entirety by this Agreement and shall have no further
force or effect. 
 5.4    Severability. In the event one or more of the provisions of this Agreement
should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such
invalid, illegal or unenforceable provision had never been contained herein. 
 5.5    Amendment and Waiver.
Except as otherwise expressly provided herein, including but not limited to as provided in Section 5.14, this Agreement may be amended or modified, and the obligations of the Company and the rights of the Holders under this Agreement may be
waived, only upon the written consent of the Company and the holders of a majority of the then-outstanding Registrable Securities; provided, however, that the amendment or modification of Sections 3.1, 3.2, 3.6, 3.9, 3.11 and 4.1 and this
Section 5.5 shall also require the written consent of the holders of at least 70% of the then-outstanding Registrable Securities. 

5.6    Delays or Omissions. It is agreed that no delay or omission to exercise any right, power, or remedy
accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any
acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of any breach, default or
noncompliance under the Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either
under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative. 

5.7    Notices. All notices required or permitted hereunder shall be in writing and shall be deemed
effectively given: (a) upon personal delivery to the party to be notified, (b) on the date of transmission when sent by confirmed email or facsimile if sent during normal business hours of the recipient, and if sent other than during
normal business hours of the recipient, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications to the Company shall be to the Company at its principal office to the attention of the Chief Executive Officer; all
communications to an Investor shall be sent to such Investor at the address as set forth on the applicable signature page or EXHIBIT A attached hereto; or at such other address as the
Company or an Investor may designate by ten (10) days’ advance written notice to the other parties hereto. 

  
 23. 

 5.8    Attorneys’ Fees. In the event that any suit or
action is instituted under or in relation to this Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and
expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs
and expenses of appeals. 
 5.9    Titles and Subtitles. The titles of the sections and subsections of
this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 

5.10    Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company
shall issue additional shares of its Series Preferred pursuant to the Purchase Agreement, any purchaser of such shares of Series Preferred shall become a party to this Agreement by executing and delivering an additional counterpart signature page to
this Agreement and shall be deemed an “Investor,” a “Holder” and a party hereunder, as applicable. Notwithstanding anything to the contrary contained herein, if the Company shall issue Equity
Securities in accordance with Section 4.6 (c), (e) or (h) of this Agreement, any purchaser of such Equity Securities may become a party to this Agreement by executing and delivering an additional counterpart signature page to this
Agreement and shall be deemed an “Investor,” a “Holder” and a party hereunder, as applicable. 

5.11    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be
an original, but all of which together shall constitute one instrument. 
 5.12    Aggregation of Stock.
All shares of Registrable Securities held or acquired by affiliated entities or persons or persons or entities under common management or control shall be aggregated together for the purpose of determining the availability of any rights under
this Agreement, and such affiliated entities or persons may apportion such rights as among themselves in any manner they deem appropriate. 

5.13    Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed to refer to the
masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require. 

5.14    Limitation of Investor Liability; Right to Conduct Activities. 

(a)    The total liability, in the aggregate, of any Investor and its respective officers, directors, affiliates,
employees and agents, for any and all claims, losses, costs or damages, including attorneys’ and accountants’ fees and expenses and costs of any nature whatsoever or claims or expenses resulting from or in any way related to such
Investor’s breach of this Agreement or any Related Agreement (as defined in the Purchase Agreement) shall be several and not joint with the other Investors and shall not exceed the total purchase price paid to the Company by such Investor for
the purchase of its shares of Series Preferred. 
 (b)    Nothing in this Agreement or in any Related Agreement
shall restrict any Investor’s freedom to operate any of its affiliates. The Company hereby acknowledges that each Investor has stated to the Company that such Investor and its affiliates engage in a wide range of funding and investment
activities, including investments in business entities that may engage in 

  
 24. 

 
business activities that are the same or similar to or compete with that of the Company (each a “Similar Business”). Accordingly, the Company shall not seek to hold any
Investor or any of its affiliates liable for any claim arising out of, or based upon (i) the investment in or funding of a Similar Business or (ii) actions taken by such Investor or its affiliates or any officer or other representative of
such Investor or any of its affiliates to provide assistance (financial or otherwise) to such Similar Business not inconsistent with their obligations to maintain the confidentiality of, and not misappropriate or wrongfully use or disclose Company
confidential information, trade secrets, technology or intellectual property rights. 
 (c)    The amendment or
waiver of this Section 5.14 with respect to any Investor shall require the written consent of such Investor. 

5.15    Termination. This Agreement shall terminate and be of no further force or effect upon the earlier of
(i) an Acquisition; or (ii) the date three (3) years following the closing of a Qualified IPO. 
 [THIS SPACE INTENTIONALLY
LEFT BLANK] 

  
 25. 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	COMPANY:
	
	CIRIUS THERAPEUTICS, INC.
		
	By:	 	/s/ Bob Baltera
	Name: Bob Baltera
	Title: President and Chief Executive Officer

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	FRAZIER LIFE SCIENCES VIII, L.P.
	 By: FHM Life Sciences VIII, L.P.

its general partner

	
	 By: FHM Life Sciences VIII, L.L.C.,

its general partner

		
	By:	 	/s/ Daniel J. Estes
		 	Daniel J. Estes, Authorized Representative

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	NOVO HOLDINGS A/S
		
	By:	 	/s/ Thomas Dyrberg
	Name:	 	Thomas Dyrberg, under specific power of attorney
	Title:	 	Managing Partner
	
	Address:
	
	 Tuborg Havnevej 19
 DK 2900
Hellerup
 Denmark
 Attn: Heather Ludvigsen

Email: hlud@novo.dk

	
	with a copy to:
	
	 Novo Ventures (US) Inc.
 501 2nd Street, Suite 300
 San Francisco, CA 94107

Attn: Nilesh Kumar and Junie Lim
 Email: nskm@novo.dk;
jeql@novo.dk

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

INVESTOR: 
  

			
	 ADAMS STREET 2014 DIRECT VENTURE/GROWTH
FUND LP
 By: ASP 2014 Direct Management LP its General Partner

By: ASP 2014 Direct Management LLC its General Partner
 By: Adams
Street Partners, LLC its Managing Member

		
	By:	 	/s/ Elisha P. Gould III     
	Name: Elisha P. Gould III
	Title: Partner
	
	 ADAMS STREET 2015 DIRECT VENTURE/GROWTH
FUND LP
 By: ASP 2015 Direct Management LP its General Partner

By: ASP 2015 Direct Management LLC its General Partner
 By: Adams
Street Partners, LLC its Managing Member

		
	By:	 	/s/ Elisha P. Gould III    
	Name: Elisha P. Gould III
	Title: Partner
	
	 ADAMS STREET 2016 DIRECT VENTURE/GROWTH
FUND LP
 By: ASP 2016 Direct Management LP its General Partner

By: ASP 2016 Direct Management LLC its General Partner
 By: Adams
Street Partners, LLC its Managing Member

		
	By:	 	/s/ Elisha P. Gould III     
	Name: Elisha P. Gould III
	Title: Partner
	
	 ADAMS STREET 2017 DIRECT VENTURE/GROWTH
FUND LP
 By: ASP 2017 Direct Management LP its General Partner

By: ASP 2017 Direct Management LLC its General Partner
 By: Adams
Street Partners, LLC its Managing Member

		
	By:	 	/s/ Elisha P. Gould III     
	Name: Elisha P. Gould III
	Title: Partner
	
	 ADAMS STREET VENTURE/GROWTH FUND VI LP

By: ASP VG Management VI LP its General Partner
 By: ASP VG
Management VI LLC its General Partner
 By: Adams Street Partners, LLC its Managing Member

		
	By:	 	/s/ Elisha P. Gould III     
	Name: Elisha P. Gould III
	Title: Partner

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	INVESTOR:
	
	RENAISSANCE VENTURE CAPITAL FUND II, LP
	
	By: Renaissance Venture Partners GP, LLC, its General Partner
	
	By: Christopher Rizik, CEO
	
	/s/ Christopher Rizik

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	HOPEN LIFE SCIENCE FUND II, LP 
	
	 By: Hopen LS GP II, LLC
 Its:
General Partner

		
		 	 By: Hopen LS Management, LLC
 Its: Sole
Member

		
	By:	 	/s/ Mark Olesnavage
	Name: Mark Olesnavage
	Title: Managing Director

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	HOPEN 44, LLC
		
	By:	 	/s/ Mark Olesnavage
	Name: Mark Olesnavage
	Title: President

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	THE PETER F. SECCHIA TRUST
		
	By:	 	/s/ Peter F. Secchia
	Name: Peter F. Secchia
	Title: Trustee

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	JOHN WILLIAM GREEN TRUST, U/A/D APRIL 25, 2003
		
	By:	 	/s/ John W. Green
	Name: John W. Green
	Title: Trustee

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	RICHARD G. HANSEN TRUST 
		
	By:	 	/s/ Richard G. Hansen
	Name: Richard G. Hansen
	Title: Trustee

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	TH CAPITAL HOLDINGS, LLC
		
	By:	 	/s/ Kenneth G. Hungerford II

	Name:	 	Kenneth G. Hungerford II

	Title:	 	Manager

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	PETER C. & EMAJEAN COOK FOUNDATION 
		
	By:	 	/s/ Carrie L. Boer

	Name: Carrie L. Boer

	Title: Treasurer

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	INVESTOR:
	
	/s/ Russell J. Visner
	RUSSELL J. VISNER

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	INVESTOR:
	
	/s/ R. David Potgeter
	R. DAVID POTGETER

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	MARK OLESNAVAGE TRUST
		
	By:	 	/s/ Mark Olesnavage

	Name: Mark Olesnavage

	Title: Trustee

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	INVESTOR:
	
	/s/ Rolf F. Kletzien
	ROLF F. KLETZIEN

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

	
	INVESTOR:
	
	DAN HARTMAN AND KIM HARTMAN (JTWROS)
	
	/s/ Dan Hartman
	DAN HARTMAN
	
	/s/ Kim Hartman
	KIM HARTMAN

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	DOUGLAS R. MORTON, JR. REVOCABLE TRUST 
		
	By:	 	/s/ Douglas R. Morton, Jr.
	Name: Douglas R. Morton, Jr.
	Title: Trustee

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	NORTHWOOD CAPITAL, LLC
		
	By:	 	/s/ William Parfet
	Name: William Parfet
	Title:

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	LEGACY LIFE SCIENCES, LLC
		
	By:	 	/s/ Sidney J. Jansma III
	Name: Sidney J. Jansma III
	Title: Manager

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	HERITAGE HOLDING CO., LLC
		
	By:	 	/s/ Sidney J. Jansma III
	Name: Sidney J. Jansma III
	Title: Manager

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	COVENANT PROPERTIES, LLC
		
	By:	 	/s/ Sidney J. Jansma III
	Name: Sidney J. Jansma III
	Title: Co-Manager

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	DOUGLAS F. MEIJER TRUST
		
	By:	 	/s/ Illegible (as Douglas F. Meijer’s durable power of attorney)
	Name: Douglas F. Meijer
	Title: Trustee

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	HENDRICK G. MEIJER TRUST
		
	By:	 	/s/ Hendrick G. Meijer
	Name: Hendrick G. Meijer
	Title: Trustee

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	DMPB INVESTMENTS, LLC
		
	By:	 	/s/ Illegible (as Douglas F. Meijer’s durable power of attorney)
	Name: Douglas F. Meijer
	Title: Manager

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	THE COLCA FAMILY, LLC
		
	By:	 	/s/ Gerard Colca
	Name: Gerard Colca
	Title: Member

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	TWB INVESTMENTS, LLC
		
	By:	 	/s/ Thomas W. Buschert
	Name: Thomas W. Buschert
	Title: Member Manager

 EXHIBIT A 

SCHEDULE OF INVESTORS 
 Adams Street
2014 Direct Venture/Growth Fund LP 
 One North Wacker Drive, Suite 2200 

Chicago, IL 60606 
 Adams Street 2015 Direct Venture/Growth
Fund LP 
 One North Wacker Drive, Suite 2200 
 Chicago, IL
60606 
 Adams Street 2016 Direct Venture/Growth Fund LP 

One North Wacker Drive, Suite 2200 
 Chicago, IL 60606 

Adams Street 2017 Direct Venture/Growth Fund LP 
 One
North Wacker Drive, Suite 2200 
 Chicago, IL 60606 
 Adams
Street Venture/Growth Fund VI LP 
 One North Wacker Drive, Suite 2200 

Chicago, IL 60606 
 Covenant Properties, LLC 

One Riverfront Plaza 
 55 Campau NW 

Grand Rapids, MI 49503-2616 
 Dan Hartman & Kim
Hartman 
 133 6th Ave 

Kirkland, WA 98033 
 Dan & Kim Hartman 

Dan Hartman 
 Dan.Hartman@gatesfoundation.org 

Kim Hartman 
 dkks4h@gmail.com 

 DMPB Investments, LLC 

c/o Greenville Partners 
 80 Ottawa Avenue NW, Suite 101 

Grand Rapids, Michigan 49503 
 Greenville Partners (Mike Julien,
Hilary Roelofs) 
 investments@greenvilleptrs.com 
 Douglas
F. Meijer Trust 
 c/o Greenville Partners 
 80 Ottawa
Avenue NW, Suite 101 
 Grand Rapids, Michigan 49503 

Douglas R. Morton, Jr. Revocable Trust 
 1484 Old Barn
Lane 
 Highland Park, IL 60035 
 Doug Morton 

drm1234@gmail.com 
 Frazier Life Sciences VIII, L.P. 

70 Willow Road, Suite 200 
 Menlo Park, CA 94025 

Hendrik G. Meijer Trust 
 c/o Greenville Partners 

80 Ottawa Avenue NW, Suite 101 
 Grand Rapids, Michigan 49503 

Heritage Holdings, LLC 
 One Riverfront Plaza 

55 Campau NW 
 Grand Rapids, MI 49503-2616 

Hopen 44, LLC 
 171 Monroe Ave NW, Suite 410 

Grand Rapids, MI 49503 
 Hopen Life Sciences Fund II, LP

 171 Monroe Ave NW, Suite 410 
 Grand Rapids, MI 49503

 Mark Olesnavage 
 molesnavage@hopenls.com 

  
 ii. 

 Howard Cox 

356 Worth Avenue 
 Palm Beach, FL 33480 

Howard Cox 
 hcox@howardcox.com 

Julie Girts 
 jgirts@howardcox.com 

John William Green Trust, u/a/d April 25, 2003 
 563
Belvedere Dr. SE 
 Grand Rapids, MI 49506 
 John Green

 john@foundersbrewing.com 
 Legacy Life Sciences, LLC

 One Riverfront Plaza 
 55 Campau NW 

Grand Rapids, MI 49503-2616 
 Sid Jansma 

sjansma3@wolvgas.com 
 Dave Rozendal 

drozendal@wolvgas.com 
 Mark Olesnavage Trust 

PO Box 141454 
 Grand Rapids, MI 49514 

Mark Olesnavage 
 molesnavage@hopenls.com 

Northwood Capital, LLC 
 277 S. Rose Street, Suite 3500

 Kalamazoo, MI 49007 
 Bill Parfet 

billparfet@northwood-group.com 
 Sandi Doctor 

sandidoctor@northwood-group.com 

  
 iii. 

 Novo Holdings A/S 

Tuborg Havnevej 19 
 DK 2900 Hellerup 

Denmark 
 Attn: Heather Ludvigsen 

Email: hlud@novo.dk 
 with a copy to: 

Novo Ventures (US) Inc. 
 501 2nd Street, Suite 300 
 San Francisco, CA 94107 

Attn: Nilesh Kumar and Junie Lim 
 Email: nskm@novo.dk;
eql@novo.dk 
 Peter C. & Emajean Cook Foundation 

2900 Charlevoix Dr SE 
 Grand Rapids, MI 49546 

Carrie Boer 
 cboer@chholdings.net 

R. David Potgeter 
 1597 Manitou Lane 

Middleville, MI 49333 
 David Potgeter 

rdpotgeter@etnasupply.com 
 Renaissance Venture Capital Fund
II, LP 
 201 S. Main Street, Suite 1000 
 Ann Arbor, MI
48104 
 Jeffrey Rinvelt 
 Richard G. Hansen Trust 

7716 N. Knapp Rd. 
 PO Box 339 

Luther, MI 49656 
 Richard Hansen 

rghansen@aol.com 
 Rolf Kletzien 

10269 West Gull Lake Drive 
 Richland, MI 49083 

Rolf Kletzien 
 rkletzien@msdrx.com 

  
 iv. 

 Russell J. Visner 

25 Peartree Ln NE 
 Grand Rapids, MI 49546 

Russell Visner 
 rvisner@etnasupply.com 

TH Capital Holdings, LLC 
 5920 Tahoe Dr. SE 

Grand Rapids, MI 49546 
 Jim Teets 

JTeets@adacautomotive.com 
 Ken Hungerford 

KHungerford@adacautomotive.com 
 The Colca Family, LLC

 125 S. Kalamazoo Mall, #604 
 Kalamazoo, MI 49007 

Jerry Colca 
 jcolca@ciriustx.com 

The Peter F. Secchia Trust 
 220 Lyon Street, NW 

Suite 510 
 Grand Rapids, MI 49503 

Mark Schut 
 mark.schut@cpa.com 

Monica Taylor 
 monica@secchia.com 

TWB Investments, LLC 
 8989 Shaner Avenue 

Rockford, MI 49341 
 Tom Buschert 

tbuschert@twbcpa.com 
 William D. Johnston Trust 

211 S. Rose Street 
 Kalamazoo, MI 49007 

Bill Johnston 
 bill@greenleaftrust.com 

Mike Elliston 
 melliston@greenleafcompanies.com 

Darla Barbarini 
 dbarbarini@greenleaftrust.com 

  
 v.EX-4.3

 Exhibit 4.3 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW. 
 WARRANT TO PURCHASE STOCK 

 

			
	Corporation:	  	CIRIUS THERAPEUTICS, INC.
	Number of Shares:	  	145,631, plus all Additional Shares which Holder is entitled to purchase pursuant to Section 1.7
	Class of Stock:	  	Series A-2 Preferred Stock
	Warrant Price:	  	$1.03 per share
	Issue Date:	  	March 6, 2018
	Expiration Date:	  	March 6, 2028

 THIS WARRANT CERTIFIES THAT, for good and
valuable consideration, the receipt of which is hereby acknowledged, PACIFIC WESTERN BANK or its assignee or transferee (“Holder”) is entitled to purchase the
number of fully paid and nonassessable shares of the class of securities (the “Shares”) of the corporation (the “Company”) at the initial exercise price per Share (the “Warrant
Price”) all as set forth above and as adjusted pursuant to Article 2 of this warrant, subject to the provisions and upon the terms and conditions set forth in this warrant. Reference is made to Section 5.4 of this warrant, whereby
Pacific Western Bank shall transfer this warrant to its parent company, PacWest Bancorp. 
 This warrant is being issued in connection with
the execution of that certain Loan and Security Agreement, dated as of March 6, 2018 by and between the Company and Holder (the “Loan Agreement”). 

ARTICLE 1 
 EXERCISE

 1.1    Method of Exercise. Holder may exercise this warrant by delivering this warrant and a duly
executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth in Section 1.2, Holder shall also deliver to the Company a check or
wire transfer of immediately available funds for the aggregate Warrant Price for the Shares being purchased. 

1.2    Conversion Right. In lieu of exercising this warrant as specified in Section 1.1, Holder may
from time to time convert this warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise of this warrant minus the
aggregate Warrant Price of such Shares by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Section 1.3. 

1.3    Fair Market Value. If the Shares are traded regularly in a public market, the fair market value of
the Shares shall be the closing price of the Shares (or the closing price of the 

 
Company’s stock into which the Shares are convertible) reported for the business day immediately before Holder delivers its Notice of Exercise to the Company. If the Shares are not regularly
traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable good faith judgment. 

1.4    Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this warrant,
the Company shall deliver to Holder certificates for the Shares acquired and, if this warrant has not been fully exercised or converted and has not expired, a new warrant representing the Shares not so acquired. 

1.5    Replacement of Warrants. On receipt of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of this warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, on surrender and
cancellation of this warrant, the Company at its expense shall execute and deliver, in lieu of this warrant, a new warrant of like tenor. 

1.6    Treatment of Warrant Upon Acquisition of the Company. 

1.6.1    “Acquisition.” For the purpose of this warrant, “Acquisition”
means (a) any sale, license, or other disposition of all or substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization, consolidation, merger or sale of the voting securities of the Company
or any other transaction where the holders of the Company’s securities before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction. 

1.6.2    Exercise Upon Acquisition. Upon the closing of any Acquisition in which the consideration to be
received by the Company’s stockholders consists of cash, marketable securities, or a combination of both cash and marketable securities, this warrant shall be automatically converted pursuant to Section 1.2, and thereafter Holder shall
participate in the Acquisition on the same terms as other holders of the same class of securities of the Company. 

1.6.3    Assumption of Warrant. Upon the closing of any Acquisition not referred to in Section 1.6.2,
Company shall have the option either to (a) cause the successor entity to assume the obligations of this warrant, and this warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the
Shares issuable upon exercise of the unexercised portion of this warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this
warrant; or (b) purchase this warrant for cash upon the closing of the Acquisition for an amount per Share equal to one (1) times the Warrant Price. 

1.7    Additional Shares. Upon the funding of the first Term Loan (as defined in the Loan Agreement) under
Tranche B (as defined in the Loan Agreement), the Company shall be deemed to have automatically granted to Holder, in addition to the number of Shares which this Warrant can otherwise be exercised for by Holder, the right to purchase 97,088
additional Shares (such additional shares being called the “Additional Shares”). 

  
 2. 

 ARTICLE 2 

ADJUSTMENTS TO THE SHARES 

2.1    Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its common stock payable
in common stock, or other securities, or subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and
kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend or subdivision occurred. 

2.2    Reclassification, Exchange or Substitution. Upon any reclassification, exchange, substitution, or
other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this warrant, Holder shall be entitled to receive, upon exercise or conversion of this warrant, the number and kind of
securities and property that Holder would have received for the Shares if this warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event shall include any automatic conversion of the
outstanding or issuable securities of the Company of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation upon the closing of a registered public offering of the
Company’s common stock. The Company or its successor shall promptly issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable
to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable upon exercise of the new warrant. The provisions of this Section 2.2 shall
similarly apply to successive reclassifications, exchanges, substitutions, or other events. 

2.3    Adjustments for Combinations, Etc. If the outstanding Shares are combined or consolidated, by
reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are split or subdivided, by reclassification or otherwise, into a greater number of shares, the Warrant
Price shall be proportionately decreased. 
 2.4    Adjustments for Diluting Issuances. In the event of
the issuance (a “Diluting Issuance”) by the Company after the Issue Date of securities at a price per share less than the Warrant Price (as adjusted for reclassifications, exchanges, substitutions, combinations,
consolidations, splits, subdivisions or other events relating to the Shares after the date hereof), then the number of shares of common stock issuable upon conversion of the Shares shall be adjusted in accordance with those provisions of the
Company’s Certificate of Incorporation that apply to Diluting Issuances. For purposes of clarification, with respect to any Diluting Issuance, if the requisite number of the Company’s stockholders waive their rights to any such adjustment
under the Company’s Certificate of Incorporation or if the Company’s Certificate of Incorporation is amended for the purposes of avoiding an adjustment to the number of shares of common stock issuable upon conversion of the Shares (or
already provides a carve-out for the purposes of avoiding an adjustment to the number of shares of common stock issuable upon conversion of the Shares), such waiver or amendment (or carve-out) shall also operate to waive any rights under this 

  
 3. 

 
Section 2.4 with respect to such Diluting Issuance (but not the rights of the Holder with respect to any subsequent Diluting Issuance). 

2.5    Certificate as to Adjustments. Upon each adjustment of the Warrant Price, the Company at its expense
shall promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a
certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price. 

2.6    Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of this warrant
and the Number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of this warrant, the Company shall eliminate such fractional share interest by paying
Holder the amount computed by multiplying the fractional interest by the fair market value of a full Share. 
 ARTICLE 3 

REPRESENTATIONS AND COVENANTS OF THE COMPANY 

3.1    Representations and Warranties. The Company hereby represents and warrants to the Holder as follows:

 (a)    The initial Warrant Price referenced on the first page of this warrant is the per share price paid in
the Company’s most recent equity financing. 
 (b)    All Shares which may be issued upon the exercise of the
purchase right represented by this warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for
restrictions on transfer provided for herein or under applicable federal and state securities laws. 
 (c)    The
Company’s capitalization table attached to this warrant is true and complete as of the Issue Date. 

3.2    Notice of Certain Events. The Company shall provide Holder with not less than 10 days prior written
notice of, including a description of the material facts surrounding, any of the following events: (a) declaration of any dividend or distribution upon its common stock, whether in cash, property, stock, or other securities and whether or not a
regular cash dividend; (b) offering for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights; (c) effecting any reclassification or recapitalization
of common stock; or (d) the merger or consolidation with or into any other corporation, or sale, lease, license, or conveyance of all or substantially all of its assets, or liquidation, dissolution or winding up. 

3.3    Information Rights. So long as the Company is not a public company and the Holder holds this warrant
and/or any of the Shares, the Company shall deliver to the Holder (a) promptly after mailing, copies of all communiques to the stockholders of the Company, (b) within 

  
 4. 

 
one hundred eighty (180) days after the end of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of
recognized standing and (c) within forty-five (45) days after the end of each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited financial statements. 

3.4    Registration Under Securities Act of 1933, as amended. At such next time hereafter as the Company
seeks the approval or consent of the investors party to the Company’s Investor Rights Agreement (the “Rights Agreement”), for any purpose, the Company shall concurrently therewith use its best efforts to obtain the
requisite consent of such parties to add the Holder as an “Investor” (as defined in the Rights Agreement) for purposes of the “piggyback” registration rights provided pursuant to Section 2.3 of the Rights Agreement. Holder
acknowledges that the Rights Agreement may be amended and the obligations under the Rights Agreement may be waived with the consent of the Company and the holders of a majority of then-outstanding Registrable Securities (as defined in the Rights
Agreement). 
 ARTICLE 4 

REPRESENTATIONS AND COVENANTS OF THE HOLDER 

4.1     Purchase for Own Account. This warrant and the securities to be acquired upon exercise of this
warrant by the Holder will be acquired for investment for the Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Securities Act of 1933, as amended (the
“Act”). Holder also represents that the Holder has not been formed for the specific purpose of acquiring this warrant or the Shares. 

4.2    Disclosure of Information. The Holder has received or has had full access to all the information it
considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this warrant and its underlying securities. The Holder further has had an opportunity to ask questions and receive answers from the Company
regarding the terms and conditions of the offering of this warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense)
necessary to verify any information furnished to the Holder or to which the Holder has access. 

4.3    Investment Experience. The Holder understands that the purchase of this warrant and its underlying
securities involves substantial risk. The Holder has experience as an investor in securities of companies in the development stage and acknowledges that the Holder can bear the economic risk of such Holder’s investment in this warrant and its
underlying securities and has such knowledge and experience in financial or business matters that the Holder is capable of evaluating the merits and risks of its investment in this warrant and its underlying securities and/or has a preexisting
personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables the Holder to be aware of the character, business acumen and financial circumstances of such
persons. 
 4.4    Accredited Investor Status. The Holder is an “accredited investor” within the
meaning of Regulation D promulgated under the Act. 

  
 5. 

 4.5    The Act. The Holder understands that this warrant
and the Shares issuable upon exercise or conversion hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment
intent as expressed herein. The Holder understands that this warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities
laws, or unless exemption from such registration and qualification are otherwise available. In addition, the Holder understands that the certificate(s) evidencing the Shares will be imprinted with a legend which prohibits the transfer of the Shares
unless they are registered or such registration is not required. 
 4.6    Market Stand-Off Agreement. The Holder agrees that the Shares (and any shares of common stock into which the Shares may be converted and any other securities issued to the Holder by the Company) shall be subject
to the market standoff provisions in Section 2.11 of the Rights Agreement. 
 ARTICLE 5 

MISCELLANEOUS 

5.1    Term: Exercise Upon Expiration. This warrant is exercisable in whole or in part, at any time and from
time to time on or before the Expiration Date set forth above. If this warrant has not been exercised prior to the Expiration Date, this warrant shall be deemed to have been automatically exercised on the Expiration Date by “cashless”
conversion pursuant to Section 1.2. 
 5.2    Legends. This warrant and the Shares (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE
WITH APPLICABLE LAW. 
 5.3    Compliance with Securities Laws on Transfer. This warrant and the Shares
issuable upon exercise of this warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state
securities laws by the transferor and the transferee. The Company shall not require Holder to provide an opinion of counsel if the transfer is to PacWest Bancorp or any other affiliate of Holder or if there is no material question as to the
availability of current information as referenced in Rule 144(c), Holder represents that it has complied with Rule 144 (d) and (e) in reasonable detail, the selling broker represents that it has complied with Rule 144(f), and the Company is
provided with a copy of Holder’s notice of proposed sale. 
 5.4    Transfer Procedure. After receipt
by Pacific Western Bank of this warrant, Pacific Western Bank will transfer all of this warrant to its parent company, PacWest Bancorp. Subject to the provisions of Section 5.3, Holder may transfer all or part of this warrant or the Shares
issuable upon exercise of this warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the portion of the warrant being 

  
 6. 

 
transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this warrant to the Company for reissuance to the transferee(s) (and Holder, if
applicable). No surrender or reissuance shall be required for the transfer to PacWest Bancorp or a transfer to any other affiliate of Holder. The Company may refuse to recognize a transfer of this warrant or the Shares to any person who directly
competes with the Company (as reasonably determined in good faith by the Company’s board of directors, but in no event shall an affiliate of Holder be deemed a competitor of Company), unless, in either case, (i) the stock of the Company is
publicly traded, or (ii) such transfer is in connection with an Acquisition of the Company by such a direct competitor. 

5.5    Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be
deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or
such Holder from time to time. All notices to the Holder shall be addressed as follows: 
 PacWest Bancorp 

Attn: Warrant Administrator 
 406
Blackwell Street, Suite 240 
 Durham, NC 27701 

5.6    Amendments. This warrant and any term hereof may be changed, waived, discharged or terminated only by
an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7    Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and
provisions of this warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8    Governing Law. This warrant shall be governed by and construed in accordance with the laws of the
State of Delaware, without giving effect to its principles regarding conflicts of law. 
 [Signature Page Follows] 

  
 7. 

 IN WITNESS WHEREOF, the undersigned has executed this Warrant to Purchase Stock as of the date set forth
above. 
  

			
	CIRIUS THERAPEUTICS, INC.
		
	By:	 	/s/ Robert F. Baltera    
		
	Name:	 	Robert F. Baltera    
		
	Title:	 	CEO    
	
	PACIFIC WESTERN BANK
		
	By:	 	/s/ Sean Noonan    
		
	Name:	 	Sean Noonan    
		
	Title:	 	Vice President    

 [Signature Page to Warrant to Purchase Stock] 

 APPENDIX 1 

NOTICE OF EXERCISE 

1.    The undersigned hereby elects to purchase ______________ shares of the ______________ stock of CIRIUS
THERAPEUTICS, INC. pursuant to the terms of the attached warrant, and tenders herewith payment of the purchase price of such shares in full. 

1.    The undersigned hereby elects to convert the attached warrant into shares in the manner specified in the
warrant. This conversion is exercised with respect to ______________ of the shares covered by the warrant. 
 [Strike paragraph that does
not apply.] 
 2.    Please issue a certificate or certificates representing said shares in the name of the
undersigned or in such other name as is specified below: 
  

	
	 
	(Holder’s Name)
	
	   

	 
	(Address)

 3.    The undersigned represents it is acquiring the shares solely for its own
account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws. 
  

	
	PACWEST BANCORP or Registered Assignee
	
	   

	(Signature)
	
	   

	(Date)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]